SLC5A2 and hydrops fetalis: It is possible that these anti-arrhythmic properties of SGLT2 inhibitors contributed to the reduction in cardiovascular mortality seen in the landmark DAPA-HF (91), EMPEROR-Reduced (92) and EMPA-REG OUTCOME (93) clinical trials.